Abiomed, Inc. (NasdaqGS:ABMD) acquired the remaining stake in preCARDIA, Inc. for $87.8 million on May 28, 2021.

Abiomed, Inc. (NasdaqGS:ABMD) completed the acquisition of the remaining stake in preCARDIA, Inc. on May 28, 2021. Frédéric Cohen, Mark Haddad, Cazals Manzo Pichot and Citrin Cooperman of Foley Hoag LLP acted as legal advisor to Abiomed. Hervé de Kervasdoué of Beylouni Carbasse Guény Valot Vernet acted as legal advisor to preCARDIA. Hervé de Kervasdouéo of BG2V acted as legal advisor to seller. Abiomed, Inc. acquired preCARDIA for a purchase price of $ 115.2 million, with a potential payout of $5 million payable based on achievement of a commercial milestone. The purchase price included cash consideration of $82.8 million for the remaining interest in preCARDIA, paid to the selling shareholders and for transaction costs associated with the acquisition and $32.4 million representing Abiomed's previously owned minority interest in preCARDIA.